Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.42 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971955 | 0.86 | P2RX7 (0.44) | SLC6A9P2RX7EIF4A3NR1H2NR1H3 | |
| SCHEMBL19985023 | 0.84 | SLC6A9 (0.47) | SLC6A9EIF4A3NR1H2NR1H3CA12 | |
| SCHEMBL19971958 | 0.83 | MAPT (0.47) | HTT | |
| SCHEMBL18286135 | 0.74 | HSP90AA1 (0.52) | P2RX7TSHRHTT | |
| SCHEMBL22055741 | 0.73 | POLB (0.57) | SLC6A9TSHRHTTNR1H2NR1H3 | |
| SCHEMBL19985025 | 0.73 | ABCB1 (0.43) | P2RX7EIF4A3TSHRHTT | |
| SCHEMBL18436642 | 0.70 | MEN1 (0.55) | SLC6A9TSHRHTTNR1H2NR1H3 | |
| SCHEMBL18283321 | 0.69 | PREP (0.62) | TSHRNAMPT | |
| SCHEMBL3781730 | 0.68 | SLC6A9 (0.43) | SLC6A9NR1H2NR1H3 | |
| SCHEMBL18286158 | 0.68 | PREP (0.58) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | SLC6A9 4318/4885P2RX7 4831/4885EIF4A3 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.